Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
so we need to dig deeper into Memory T cells ........... and what Mab 2811 is giving us ... and what can it do ?
TSCM have been demonstrated to exhibit characteristics closer to those of conventional memory T cells compared with naïve T cells. The T-cell receptor (TCR) rearrangement excision circles, which are diluted during clonal proliferation, were found to be of a lower copy number in TSCM compared with naïve T cells, similar to other memory T cells (CM and EM). This indicated that TSCM had undergone multiple rounds of division.15 In addition, upon TCR stimulation, TSCM are antigen experienced and exhibit effector activity including tumor necrosis factor alpha, IFN-? and IL-2 secretion, whereas naïve T cells were reported to remain relatively quiescent.15 Gattinoni et al.15 demonstrated TSCM to differentiate into CM and EM T-cell subsets, and compared with CM and EM T cells, showed TSCM to have a greater self-renewal capacity in the presence of IL-15 homeostatic signals and to be longer lived.15
So it looks like these T cells are very experienced in other words that have fought wars before and Darwins theory comes in to play .. elite " t cells"
""" In addition, upon TCR stimulation, TSCM are antigen experienced and exhibit effector activity including tumor necrosis factor alpha, IFN-? and IL-2 secretion """
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4232066/
These Mabs are multi functional as per the presentation so you have just seen the ADC (antibody Drug Conjugate) effect with fluorescence allowing surgeons to identify clearly rogue cells ... imagine a cancer that is growing around something ... and you have that level of identification ..
really is exciting stuff ........
https://www.scancell.co.uk/Data/Sites/1/media/docspres/presentation-to-lsx-world-congress-february-2020.pdf
Slide 17 of this recent presentation is a good summary of the 5 glycans mabs.
On top of that you have the concept of Avidimab that can be applied to any mab.
Also note that mab2811 has the potential to expand the population of TSCMs in order to attack a solid tumour of your choice as long as it recognises the particular TCR of the TSCM. This could be effected by the TSCM expansion itself or via TCR or via Car-T.
Which sounds like that first collab is going to plan so any deal will be done with at least year of looking closely in lab experimentation at the MaBs and Avidimab in all their potential ..... obviously, a deal after that would also be a great boost to the value of IP as that is a 3rd party saying yes we have tried and we have liked enough to do a deal it could also be a very interesting deal seeing at just how much potential there is in Avidimab and the glycans
As I understand it, mab2811 has a very different concept to the other glycans mabs.
It targets TSCMs to stimulate expansion rather than attacking the tumour. Hence at the Paris conference it had its own poster.
It may be treated separately if and when it comes to a deal.
There are so many permutations for a possible deal so we could have a prolonged set of talks.
Don't forget what was said in the rns announcing the placing regarding Avidimab (and I cut and paste here for accuracy) - 'Advanced commercial discussions are currently underway with a global biotech with initial commercial collaboration potentially to be in the form of granting a partner an option to a future licence.'
Definitely or is it defiantly..... anyways the d word we need is deals;-)
Crumbs, you mentioned the "D" word
https://www.youtube.com/watch?v=yfl6Lu3xQW0
I hope you get away with it.
With over 15 mill in the bank.... sit back relax :) the science is being seen potential deal/s to be done across 3 platforms and multiple products with an enviable amount of targets many of them the toughest ones and moditope can now be proven in human trials by scancell itself... risk-free no..... de-risked by....... dilution lol but done by getting in some impressive ii's -yes! ....
They are being looked at in depth with partners already :
' Scancell and its partner will evaluate the potential of anti-TaG mAbs, enhanced with AvidiMab™, in various formats including, antibody drug conjugates, bispecific antibodies, as well as stand-alone antibody products.'
The first of 3 of those partnerships was expected to have a year long collab looking in full depth that year began 4th Sept 2019
So....... the first deal/s may not be too far away
Thanks Crumbs.
I assume FG2811 has been renamed.
Does Scancell employ any salesmen ?
https://www.scancell.co.uk/Data/Sites/1/media/docspres/presentation-to-lsx-world-congress-february-2020.pdf
page 15
'Broad scope and utility ? multiple licensing opportunities '
5 MaBs good to go
As you all know I don’t profess to understand the science. I’m just a money man.
My question is, is this MAB2811 good to go or does it require years and years of testing ? Wouldn’t it be nice to finally have a product that could be sold/licensed now!
There are billions who would pay good money for that LOL.
Perhaps shareholders could get discounts, in the way that other share incentives are offered to entice private holders.
Even better, the effect lasts for months.
At least the memory does.
It would command a stiff price for sure.
No problem Chester.
If Pfizer buy it, it could be branded Viagramab.
SuperMab
Thanks Ray I was disappointed that nobody was playing........ : )
Chester
Just the normal run of the mill conclusions for Mab2811
From the poster again:
Conclusions
1) SSEA-4 is a novel marker for human and mouse TSCMs.
2) 2811 mAb able to identify, isolate and expand putative TSCM in vitro and in vivo.
3) 2811+ T cells are potential candidates for genetic manipulation to express antigen specific TCRs or CARs.
4) 2811 is a potential T cell agonistic mAb
Number 3) may have been noticed by Biontech amongst others.
But be careful, Supermab may be weakened by green kyrptonite :-)
Inan,
Yes it was you that led me to MAB2811, think you mentioned it was fascinating, so I certainly won't take credit for posting on it.
Just think your mention of it may have been missed by all the incoming flak!!.... that's why I flagged it up again a couple of times.
I am hungry for more info on it though
ATB
Bunsie
Inanaco, from your research......only!!.................what kind of value would you proportion 2811 at, if ultimately we can use it for licensing out????
Been saying this for months ...... 2811 is highly valuable .. because it can be licensed multiple times as a "tool" for anthers process
Another remarkable piece of detective work by Prof Lindy and Co.
The knowledge within Scancell under her tutelage is amazing for such a small but dedicated team.
As we have come to call 'The Pound Shop Bio-Tech' ... I think I've got that right....
So just for a bit of fun lets offer up some names for Mab2811 ........ If an Avidity producing Mab is 'AvidiMab' what can we call a Self Renewing, Highly Proliferating, Super Anti-Tumour, Multi-Potent, Effector & Memory 'T Cell' Building ----- Mab.
My initial thoughts are that its like the Higgs Boson ( The God Particle ) so I'm going for : 'ZeusMab' ... lol
Chester.
Morning Bunsie
Unlike Immunobody and Moditope vaccines which activate naive T Cells via Antigen Presenting Cells, MAB2811 is aimed at existing TSCMs.
I think the idea is that TSCMs are the top level of memory TCells.
They will differentiate into other types of memory TCells.
So, if you have a mechanism for expanding the population of the TSCMs then you are in effect boosting the populations of all the other types of memory TCells including those that become effector cells when the antigen re-appears.
But the article also says that TSCMs could be a powerful force in their own right.
So MAB2811 looks like it applies a double whammy by increasing the population of TSCMs and by doing this also increasing the populations of the other types of memory T Cells.
This also is thought provoking from the Paris poster:
"At day 35, under light microscope, cells stimulated with anti-CD3 mAb and unstimulated cells
were all dead except cells stimulated with 2811 mAb."
Probably very early days in whatever Lindy has got planned, but to me it looks like a very powerful mAB.
Morning Ray,
Thanks for that link yesterday, just took a look this morning.
Doesn't seem to be much more information out there yet on this..... whatever are Scancell up to? another gem perhaps.
Would be good if our BB CSO's could spend some time next week on this, very interesting
ATB
Bunsie